Ivabradine Viatris (Ivabradine Oxalate)

Ivabradine acts on the cardiac If channel to lower heart rate, benefiting several cardiovascular conditions.

• Chronic stable angina pectoris: reduces heart rate, improving exercise tolerance and decreasing angina episodes.
• Heart failure with reduced ejection fraction: lowers heart rate, contributing to improved ventricular remodeling and reduced hospitalizations.
• Symptomatic tachycardia in patients on beta‑blockers: provides additional heart‑rate control when beta‑blocker therapy alone is insufficient.

• Ivabradine selectively binds to the hyperpolarization‑activated cyclic nucleotide‑gated (HCN) channels that generate the funny (If) current in sino‑atrial node pacemaker cells. By inhibiting this inward sodium/potassium current, the drug slows depolarisation during phase 4, resulting in a reduction of spontaneous heart‑rate without altering myocardial contractility, atrioventricular conduction, or blood pressure. The effect is dose‑dependent and reversible, allowing heart rate to return toward baseline after discontinuation.

Ivabradine may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Visual disturbances (phosphenes)
• Bradycardia
• Headache
• Dizziness

Serious or Rare Side Effects

• Symptomatic atrial fibrillation
• Severe bradycardia requiring intervention
• Persistent visual impairment

When prescribing ivabradine, clinicians should observe several precautions to ensure safe use.

• Heart rate monitoring: check resting heart rate before initiation and periodically thereafter.
• Contraindication in severe hepatic impairment: avoid use in patients with Child‑Pugh class C liver disease.
• Caution with concomitant beta‑blockers: assess for excessive bradycardia when combined.
• Assess for atrial fibrillation: discontinue if new‑onset atrial fibrillation occurs.
• Pregnancy and lactation: use only if potential benefit justifies potential risk; limited data available.
• Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Ivabradine interacts with several medicines that can alter its plasma concentration or additive heart‑rate effects.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase ivabradine levels.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may markedly reduce ivabradine efficacy.
• Other heart‑rate lowering agents (e.g., digoxin, beta‑blockers): risk of excessive bradycardia.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may increase ivabradine exposure.
• Antihypertensive drugs: monitor blood pressure for additive effects.
• QT‑prolonging agents: observe ECG for potential prolongation.